Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect

Journal of Controlled Release

Volumn 143, Issue 1, 2010, Pages 136-142

  Zhan, Changyou ^a   Gu, Bing ^a   Xie, Cao ^a   Li, Jin ^a   Liu, Yu ^a   Lu, Weiyue ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

C(RGDyK); Glioblastoma; Paclitaxel; PEG PLA micelle

Indexed keywords

ARGININE-GLYCINE-ASPARTIC ACIDS; BINDING AFFINITIES; BIODISTRIBUTIONS; CENTRAL NERVOUS SYSTEMS; CHEMOTHERAPEUTIC AGENTS; COMPETITIVE BINDING; CYTOTOXIC; D-TYROSINE; GLIOBLASTOMA; GLIOBLASTOMA CELLS; GLIOBLASTOMAS; IN-VITRO; INTEGRINS; INTRACRANIAL TUMORS; INTRAVENOUS ADMINISTRATION; LOADING CAPACITIES; MEDIAN SURVIVAL; NEOVASCULATURE; NUDE MICE; PACLITAXEL; PHARMACOLOGICAL EFFECTS; PHYSICO-CHEMICAL CHARACTERIZATION; POLY(LACTIC ACID); POTENTIAL DRUG; RGD PEPTIDE; TARGETED DRUG DELIVERY; TUMOR GROWTH; TUMOR XENOGRAFTS;

AMINO ACIDS; BEARINGS (STRUCTURAL); BINDING ENERGY; BODY FLUIDS; DRUG DELIVERY; DRUG DOSAGE; ETHYLENE; ETHYLENE GLYCOL; LACTIC ACID; MICELLES; ORGANIC ACIDS; PHOSPHATASES; POLYETHYLENE OXIDES; TUMORS;

POLYETHYLENE GLYCOLS;

ARGINYLGLYCYLASPARTIC ACID; COPOLYMER; CYCLOPEPTIDE; IODINE 125; PACLITAXEL; POLY(ETHYLENE GLYCOL) CO POLY(LACTIC ACID); UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CANCER SURVIVAL; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; GENE EXPRESSION; GLIOBLASTOMA; IC 50; IN VITRO STUDY; ISOTOPE LABELING; MICELLE; MOUSE; NONHUMAN; NUDE MOUSE; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT DURATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; GLIOBLASTOMA; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; INTEGRIN ALPHAVBETA3; LACTATES; MICE; MICE, NUDE; MICELLES; PACLITAXEL; PARTICLE SIZE; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; TECHNOLOGY, PHARMACEUTICAL; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950515941     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.12.020     Document Type: Article

References (27)

1. Jain R.K., Tomaso E., Duda D.G., et al. Angiogenesis in brain tumors. Nat. Rev. Neurosci. 2007, 8:610-622.
2. Ong B.Y., Ranganath S.H., Lee L.Y., et al. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials 2009, 30:3189-3196.
3. Régina A., Demeule M., Ché C., et al. Antitumor activity of ANG 1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 2008, 155:185-197.
4. Nikanjam M., Gibbs A.R., Hunt C.A., et al. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J. Control Release 2007, 124:163-171.
5. Desai A., Vyas T., Amiji M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J. Pharm. Sci. 2008, 97:2745-2756.
6. Son M.J., Song H.S., Kim M.H., et al. Synergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastoma. Int. J. Oncol. 2006, 28:1385-1392.
7. Brem H., Gabikian P. Biodegradable polymer implants to treat brain tumors. J. Control Release 2001, 74:63-67.
8. Li J., Strobel G., Sidhu R., et al. Endophytic taxol-producing fungi from bald cypress, taxodium distichum. Microbiology 1996, 142:2223-2226.
9. Fang G.F., Chang B.S., Kim C.N., et al. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res. 1998, 58:3202-3208.
10. Rodi D.J., Janes R.W., Sanganee H.J., et al. Screening of a library of phage-displayed peptides identifies human Bcl-2 as a taxol-binding protein. J. Mol. Biol. 1999, 285:197-203.
11. Musacchio T., Laquintana V., Latrofa A., et al. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol. Pharm. 2008, 6:468-479.
12. 3-integrin expression in vivo. Acc. Chem. Res. 2009, 42:969-980.
13. Chen X., Plasencia C., Hou Y., et al. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J. Med. Chem. 2005, 48:1098-1106.
14. Chen X., Park R., Shahinian A.H., et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl. Med. Biol. 2004, 31:179-189.
15. Chen X., Hou Y., Tohme M., et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J. Nucl. Med. 2004, 45:1776-1783.
16. Chen K., Xie J., Xu H., et al. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials 2009, 10.1016/j.biomaterials.2009.08.045.
17. Nasongkla N., Bey E., Ren J., et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano. Lett. 2006, 6:2427-2430.
18. Han L.M., Guo J., Zhang L.J., et al. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta. Pharmacol. Sin. 2006, 27:747-753.
19. Chen X., Conti P.S., Moats R.A. In vivo near-infrared fluorescence imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res. 2004, 64:8009-8014.
20. Cai W., Chen X. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat. Protoc. 2008, 3:89-96.
21. Park K., Kim Y.S., Lee G.Y., et al. Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm. Res. 2008, 25:2786-2798.
22. Zhao H., Wang J.C., Sun Q.S., et al. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J. Drug Target 2009, 17:10-18.
23. Saad M., Garbuzenko O.B., Ber E., et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?. J. Control Release 2008, 130:107-114.
24. Hoffmann J., Fichtner I., Lemm M., et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro. Oncol. 2009, 11:158-166.
25. 3-target magnetic resonance imaging. Nat. Med. 1998, 44:623-626.
26. Chen X., Park R., Khankaldyyan V., et al. Longitudinal MicroPET imaging of brain tumor growth with F-18-labeled RGD peptide. Mol. Imaging Biol. 2006, 8:9-15.
27. Ong H.T., Trejo T.R., Pham L.D., et al. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol. Ther. 2009, 17:1012-1021.